A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies. About 60% of pediatric patients had side effects, mostly mild. Read the Pediatric Cardiology article

Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was then able to get a liver transplant. However, they did note some risks. Read the Communications Medicine article

Researchers conducted a meta-analysis, looking at 13 studies with about 700 participants in total with pulmonary hypertension (PH). They found that exercise improved 6-minute walk distance and was consistently well-tolerated by PH patients, and there were no serious adverse events directly linked to the exercise activities in the studies. Read the European Journal of Applied Physiology article